Prevention of metabolic syndrome from atypical antipsychotic medications: Applying rogers' diffusion of innovations model in clinical practice

Journal of Psychosocial Nursing and Mental Health Services

Volumn 50, Issue 12, 2012, Pages 36-44

  Parrinello, Michael C ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870935884     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20121107-02     Document Type: Article

References (12)

1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on an-tipsychotic drugs and obesity and diabetes. Diabetes Care, 27. Retrieved from http://pro-fessional.diabetes.org/admin/UserFiles/file/CE/AntiPsych%20Meds/Consensus%20paper.pdf
2. De Civita, M., & Dasgupta, K. (2007). Using dif-fusion of innovations theory to guide diabetes management program development: An illus-trative example. Journal of Public Health, 29, 263-268. doi:10.1093/pubmed/fdm033
3. Després, J.-P., Lemiuex, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E.,. Poirer, P. (2008). Abdominal obesity and the metabolic syn-drome: Contribution to global cardiometabolic risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 1039-1049. doi:10.1161/ATVBA-HA.107.159228
4. Esteve, E., Ricart, W., & Fernández-Real, J.M. (2009). Adipocytokines and insulin resis-tance. Diabetes Care, 32(Suppl. 2), S362-S367. doi:10.2337/dc09-S340
5. Goldberg, R.W., Kreyenbuhl, J.A., Medoff, D.R., Dickerson, F.B., Wohlheiter, K., Fang, L.J.,.Dixon, L.B. (2007). Quality of diabetes care among adults with serious mental illness. Psychiatric Services, 58, 536-543.
6. Hamdy, O., Porramatikul, S., & Al-Ozairi, E. (2006). Metabolic obesity: The paradox between visceral and subcutaneous fat. Current Diabetes Reviews, 2, 367-373.
7. Hasnain, M., Vieweg, W.V., Fredrickson, S.K., Beatty-Brooks, M., Fernandez, A., & Pandurangi, A.K. (2009). Clinical monitoring and manage-ment of the metabolic syndrome in patients re-ceiving atypical antipsychotic medications. Primary Care Diabetes, 3(1), 5-15. doi:10.1016/j.pcd.2008.10.005
8. Khatana, S.A.M., Kane, J., Taveira, T.H., Bauer, M.S., & Wu, W.-C. (2011). Monitoring and prevalence rates of metabolic syndrome in military veterans with serious mental illness. PLoS ONE, 6(4). Retrieved from http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0019298. doi:10.1371/journal.pone.0019298
9. Mathieu, P., Poirier, P., Pibarot, P., Lemieux, I., & Després, J.P. (2009). Visceral obesity: The link among inflammation, hypertension, and car-diovascular disease. Hypertension, 53, 577-584.
10. Mendelson, S.D. (2008). Metabolic syndrome and psychiatric illness: Interactions, pathophysiology, assessment and treatment. Burlington, MA: Academic Press.
11. Nasrallah, H.A., Meyer, J.M., Goff, D.C., McEvoy, J.P., Davis, S.M., Stroup, T.S., & Lieberman, J.A. (2006). Low rates of treatment for hyper-tension, dyslipidemia, and diabetes in schizo-phrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research, 86, 15-22.
12. Rogers, E.M. (1962). Diffusion of innovations. New York: The Free Press.